ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements
Promoter Sachidanand Hariram Upadhyay proposed reinvesting proceeds from his prior sale of shares into the company's medical device unit expansion.
Lord’s Mark Industries has advanced its AI-powered breast cancer screening technology to final clinical trial stages. The company targets a global commercial launch by April 2027.
Promoter Director Mr. Sachidanand H Upadhyay sold 1.04 crore shares on BSE for ₹87.39 Crore. Stake reduced from 77.54% to 75.11%.
Lord's Mark promoter Sachidanand Upadhyay disposed 1.04 crore shares via open market, cutting his stake from 77.54% to 75.11%.
Lord's Mark Industries completed Phase I Silvassa expansion, adding 18 surgical/orthopaedic SKUs (36 to 54). Commercial operations commence October 11, 2026.
Lord's Mark Industries is a MedTech and Renewable Energy conglomerate focused on high-margin diagnostic innovations and a ₹3,000+ Cr solar order pipeline.
The board approved a proposal for an Offer for Sale (OFS) of up to 3% of equity capital by promoters to meet minimum public shareholding requirements.
Lords Mark Industries Ltd has issued a notice for its 46th Annual General Meeting, scheduled to be held on September 30, 2026.
Lord's Mark Industries Limited has filed its 46th Annual Report for the financial year 2025-26 and the notice of its upcoming 46th Annual General Meeting.
Lords Mark Industries reported Q1 FY27 results, achieving 280 Cr topline and 32 Cr bottom line. The firm is transitioning from traditional energy to high-margin MedTech and diagnostics.
Lords Mark Industries Ltd reported revenue from operations of ₹307.7 Cr and net profit of ₹33.2 Cr for Q1 FY27.